BofA reiterates Buy on IBM stock, keeps $300 price target By Investing.com

IBM reported Q1 EPS of $1.91 versus $1.81 expected and revenue of $15.92B versus $15.61B, but second-quarter pretax income guidance implied only 50bps of expansion versus about 75bps expected. BofA reiterated a Buy rating and $300 price target, citing IBM’s software mix shift, free cash flow, quantum computing optionality, and 2.67% dividend yield with a 30-year streak of dividend increases. The Confluent acquisition is expected to add about 1% inorganic growth, though management’s near-term focus remains integration.

Analysis

IBM’s setup is increasingly about multiple preservation versus multiple expansion. The software mix shift and cash generation support downside in the equity, but the market is likely to keep discounting any earnings quality that is driven by acquisition accounting or temporary cost discipline rather than durable organic acceleration. The most important second-order effect is that IBM’s capital allocation optionality improves if software valuations stay cheap: it can keep buying growth without needing heroic top-line inflection, which limits the probability of a near-term de-rating.

The weak spot is that guidance cadence matters more than the beat. A narrow increase in software outlook and softer margin trajectory suggest the business is still in “prove it” mode, so any disappointment in integration or cross-sell from the latest acquisition can hit sentiment quickly over the next 1-2 quarters. If pretax margin expansion does not re-accelerate by the next print, the stock may revert to being treated like a slow-growing software conglomerate rather than a quality compounder, especially if rates stay elevated and investors rotate toward cleaner secular growth.

The market may be underestimating how much of the upside is already embedded in the valuation through the dividend narrative. At these levels, IBM behaves like a bond proxy with modest upside unless software growth surprises sustainably above the low-teens and free cash flow converts into faster buybacks. On the other side, the article’s mention of acquisition optionality creates a hidden risk for CFLT: even if IBM is supportive of the asset class, deal speculation can compress standalone valuations in adjacent names if investors assume strategic buyers will remain active and price to takeout rather than fundamentals.

Key Decisions for Investors

• Long IBM / short QQQ for 1-2 quarters: IBM has a defensive cash-flow floor, but the equity can outperform a growth index if market pricing shifts toward quality balance sheets and dividends. Risk: if software growth re-accelerates across megacap tech, QQQ rebound can swamp relative alpha.
• Sell IBM downside puts into post-earnings volatility for 30-60 days: the stock appears supported by dividend yield and buyback capacity, making elevated implied volatility attractive to monetize. Risk: a guidance reset or acquisition misstep can create an air-pocket lower.
• Pair trade long IBM vs short a basket of high-multiple enterprise software names that depend on multiple expansion rather than cash return: IBM benefits from capital returns and integration leverage, while weaker fundamentals in the basket are more rate-sensitive. Risk/reward improves if rates remain sticky for the next 1-2 quarters.
• Cautious long CFLT only on weakness if merger premium does not materialize: IBM’s involvement can create sector read-through, but standalone holders face event-risk without guaranteed takeout timing. Better entry is after any speculative pop fades; otherwise upside is mostly binary over 3-6 months.
• If IBM fails to expand software margins in the next two reports, reduce exposure: the stock is already pricing in a premium for quality and capital returns, so absent margin confirmation the upside likely caps near the current re-rating rather than compounding materially.